Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1057 in Advanced Malignant Solid Tumors
NCT06573294Phase 1Terminated
- Sponsor
- Genmab
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of GEN1057 in malignant solid tumor, sponsored by Genmab. Primary endpoints: Treatment-emergent Adverse Events at 5 months and Dose Limiting Toxicities at 21 days. Started Aug 2024; status: terminated.
02
Drugs
GEN1057
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06573294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06573294.